OxThera Email Format

Biotechnology ResearchUnited States2-10 Employees

OxThera is a biotechnology research company based in the United States that develops therapies for rare diseases. Its lead program, Oxabact, targets Primary Hyperoxaluria, a serious, often fatal pediatric condition with limited treatment options. The firm operates as a privately held biopharmaceutical company advancing a Phase 3 clinical program for Oxabact.

As a small private company in the biopharmaceutical sector, OxThera positions its efforts within nephrology and rare-disease therapeutics. A development noted in 2018 indicated that the Phase 3 trial for Oxabact in Primary Hyperoxaluria had been opened for recruitment.

Sign up for free to view info

Company overview Employee directory